This companion diagnostic assesses non-small cell lung cancer (NSCLC) tumor samples for specific genetic alterations. It identifies biomarkers that can predict a patient’s likelihood of responding to targeted therapies, guiding treatment decisions towards personalized medicine. For instance, the assay detects alterations in genes like EGFR, ALK, ROS1, BRAF, MET, RET, NTRK1/2/3, and KRAS.
Molecular profiling through this type of diagnostic testing is critical for optimizing treatment strategies in NSCLC. By identifying targetable genetic mutations, clinicians can select the most effective therapy for individual patients, potentially maximizing treatment response and minimizing exposure to ineffective treatments and their associated side effects. This shift towards precision oncology represents a significant advancement in cancer care, moving away from a one-size-fits-all approach. The development and implementation of such diagnostics reflect a growing understanding of the molecular underpinnings of cancer and the potential for targeted therapies to improve patient outcomes.
